T2000 in Essential Tremor - Open Label Continuation
Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study
Sponsor: Sun Pharmaceutical Industries, Inc.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Sun Pharmaceutical Industries, Inc.
- Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis · Phase PHASE2 · Sep 2019
- Plaque Psoriasis · Phase PHASE4 · Aug 2019
- Active Rheumatoid Arthritis · Phase PHASE3 · Jun 2018
- Vaginal Atrophy · Phase PHASE3 · Apr 2013
- Myoclonus · Phase PHASE2 · Oct 2011
More terminations from Sun Pharmaceutical Industries, Inc.
Other Essential Tremor trials with similar outcome
This PHASE2 trial investigates Essential Tremor and is currently terminated or withdrawn. Sun Pharmaceutical Industries, Inc. leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sun Pharmaceutical Industries, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .